Literature DB >> 25806334

Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer.

Arun Rajan1, James L Gulley1.   

Abstract

Entities:  

Year:  2014        PMID: 25806334      PMCID: PMC4367666          DOI: 10.3978/j.issn.2218-6751.2014.09.02

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


× No keyword cloud information.
  8 in total

1.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

Review 2.  Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?

Authors:  Christian Rolfo; Giovanni Sortino; Evelien Smits; Francesco Passiglia; Giuseppe Bronte; Marta Castiglia; Antonio Russo; Edgardo S Santos; Annelies Janssens; Patrick Pauwels; Luis Raez
Journal:  Expert Rev Anticancer Ther       Date:  2014-08-22       Impact factor: 4.512

3.  Erlotinib in previously treated non-small-cell lung cancer.

Authors:  Frances A Shepherd; José Rodrigues Pereira; Tudor Ciuleanu; Eng Huat Tan; Vera Hirsh; Sumitra Thongprasert; Daniel Campos; Savitree Maoleekoonpiroj; Michael Smylie; Renato Martins; Maximiliano van Kooten; Mircea Dediu; Brian Findlay; Dongsheng Tu; Dianne Johnston; Andrea Bezjak; Gary Clark; Pedro Santabárbara; Lesley Seymour
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

4.  Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.

Authors:  Janis M Taube; Alison Klein; Julie R Brahmer; Haiying Xu; Xiaoyu Pan; Jung H Kim; Lieping Chen; Drew M Pardoll; Suzanne L Topalian; Robert A Anders
Journal:  Clin Cancer Res       Date:  2014-04-08       Impact factor: 12.531

5.  Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial.

Authors:  F Barlesi; A Scherpereel; V Gorbunova; R Gervais; A Vikström; C Chouaid; A Chella; J H Kim; M J Ahn; M Reck; A Pazzola; H T Kim; J G Aerts; C Morando; A Loundou; H J M Groen; A Rittmeyer
Journal:  Ann Oncol       Date:  2014-02-27       Impact factor: 32.976

6.  Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

Authors:  Nasser Hanna; Frances A Shepherd; Frank V Fossella; Jose R Pereira; Filippo De Marinis; Joachim von Pawel; Ulrich Gatzemeier; Thomas Chang Yao Tsao; Miklos Pless; Thomas Muller; Hong-Liang Lim; Christopher Desch; Klara Szondy; Radj Gervais; Christian Manegold; Sofia Paul; Paolo Paoletti; Lawrence Einhorn; Paul A Bunn
Journal:  J Clin Oncol       Date:  2004-05-01       Impact factor: 44.544

7.  Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

Authors:  Suzanne L Topalian; Mario Sznol; David F McDermott; Harriet M Kluger; Richard D Carvajal; William H Sharfman; Julie R Brahmer; Donald P Lawrence; Michael B Atkins; John D Powderly; Philip D Leming; Evan J Lipson; Igor Puzanov; David C Smith; Janis M Taube; Jon M Wigginton; Georgia D Kollia; Ashok Gupta; Drew M Pardoll; Jeffrey A Sosman; F Stephen Hodi
Journal:  J Clin Oncol       Date:  2014-03-03       Impact factor: 44.544

8.  Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy.

Authors:  Stéphane Champiat; Charles Ferté; Sophie Lebel-Binay; Alexander Eggermont; Jean Charles Soria
Journal:  Oncoimmunology       Date:  2014-01-16       Impact factor: 8.110

  8 in total
  10 in total

Review 1.  Nivolumab: a review in advanced squamous non-small cell lung cancer.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546

2.  Expression of Recombinant CTLA-4 and PD-L1 Proteins Fused with Thioredoxin, and Determination of Their Ligand-Binding Activities.

Authors:  Adish Zhansaya; Nurtleu Malika; Dzantiev Boris; Tursunov Kanat; Mukantayev Kanatbek; Ramankulov Yerlan; Mukanov Kasym
Journal:  Rep Biochem Mol Biol       Date:  2022-07

Review 3.  PD-1 and its ligands are important immune checkpoints in cancer.

Authors:  Yinan Dong; Qian Sun; Xinwei Zhang
Journal:  Oncotarget       Date:  2017-01-10

Review 4.  Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor.

Authors:  Liting Guo; Haijun Zhang; Baoan Chen
Journal:  J Cancer       Date:  2017-02-10       Impact factor: 4.207

5.  Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer.

Authors:  Jae Cheol Lee; Jin Kyung Rho; Dong Ha Kim; HyeongRyul Kim; Yun Jung Choi; Seon Ye Kim; Jung-Eun Lee; Ki Jung Sung; Young Hoon Sung; Chan-Gi Pack; Min-Kyo Jung; Buhm Han; Kunhee Kim; Woo Sung Kim; Soo Jeong Nam; Chang-Min Choi; Miyong Yun
Journal:  Exp Mol Med       Date:  2019-08-09       Impact factor: 8.718

6.  PLK1/vimentin signaling facilitates immune escape by recruiting Smad2/3 to PD-L1 promoter in metastatic lung adenocarcinoma.

Authors:  Hay-Ran Jang; Sol-Bi Shin; Chang-Hyeon Kim; Jae-Yeon Won; Rong Xu; Da-Eun Kim; Hyungshin Yim
Journal:  Cell Death Differ       Date:  2021-05-07       Impact factor: 12.067

Review 7.  Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects.

Authors:  Chunyan Shi; Yan Wang; Jianxin Xue; Xiaojuan Zhou
Journal:  Front Immunol       Date:  2022-07-22       Impact factor: 8.786

8.  Characterizing the Role of Monocytes in T Cell Cancer Immunotherapy Using a 3D Microfluidic Model.

Authors:  Sharon Wei Ling Lee; Giulia Adriani; Erica Ceccarello; Andrea Pavesi; Anthony Tanoto Tan; Antonio Bertoletti; Roger Dale Kamm; Siew Cheng Wong
Journal:  Front Immunol       Date:  2018-03-06       Impact factor: 7.561

9.  Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma.

Authors:  Manh-Cuong Vo; Sung-Hoon Jung; Tan-Huy Chu; Hyun-Ju Lee; Thangaraj Jaya Lakshmi; Hye-Seong Park; Hyeoung-Joon Kim; Joon Haeng Rhee; Je-Jung Lee
Journal:  Front Immunol       Date:  2018-06-18       Impact factor: 7.561

Review 10.  Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization.

Authors:  Ashley Y Choi; Miriam Manook; Danae Olaso; Brian Ezekian; Jaeberm Park; Kyle Freischlag; Annette Jackson; Stuart Knechtle; Jean Kwun
Journal:  Front Immunol       Date:  2021-06-11       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.